Presentation on Japan First Strategy at Ord Minnett
Presentation on Japan First Strategy at Ord Minnett
Sydney, Nov 1, 2017 AEST (ABN Newswire) - Regeneus Ltd (ASX:RGS) provides the Company's Presentation on Japan First Strategy at Ord Minnett.

Company Snapshot

3 world class-technology platforms

- Allogeneic adult stem cells (MSCs) from adipose tissue for osteoarthritis and other inflammatory conditions (Progenza, CryoShot)

- Immuno-therapy for oncology (RGSH4K, Kvax)

- Cell-free secretions from MSCs focused on dermatology and inflammatory skin conditions (Sygenus)

Diversified portfolio of clinical stage products

- Human and animal health markets

- Multiple product opportunities addressing multiple significant unmet medical needs - many shots on goal

- Technology supported by emerging positive clinical data

- Scalable manufacturing for allogeneic stem cells

- IP portfolio underpins technology and product pipeline for wide range of inflammatory indications

- Licence driven business model

Driven by innovation and collaboration

- Track record of technology innovation and rapid translation to the clinic

- Successful technology and clinical collaborations (AGC, Kolling Institute, Macquarie and Adelaide Unis)

- Experienced and commercially focused management team and Board

- Well positioned to unlock significant value over next 12 months

Japan First Strategy

- Most Australian biotechs seek to license for US and EU markets first

- Japan first strategy takes advantage of globally attractive market conditions

o fast-track regulatory environment for RM products

-- shorter phase 2 trial - "probable efficacy"

-- Conditional Approval 5-7 years means no requirement for phase 3

-- can commercialise product during CA phase

-- 70% government reimbursement includes CA phase

o supportive regulator - PMDA and government departments

o high level of industry engagement for market sector - FIRM >250 members

- Focus on product manufacturing and standardization allows for separating manufacturing and clinical licensing transactions

- Licensees willing to do Japan only transactions - benchmarks marks value and leaves other territories available

- Japan can validate opportunity for other markets

- Other jurisdictions influenced by new regulatory framework - eg South Korea and USA

To view the presentation, please visit:

About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.



Sandra McIntosh
Company Secretary and Investor Relations
M: +61-450-253059
T: +61-2-9499-8010

Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 23) (Last 30 Days: 80) (Since Published: 3533) 

Regeneus Ltd NEWS: RECENT VISITS (9367)

Research Report

Social Media